Stocks to Watch : Gilead Sciences Inc. (NASDAQ:GILD), Sprint (NYSE:S), DWSN, Prana Biotechnology Limited (NASDAQ:PRAN), Lime Energy (NASDAQ:LIME)

Gilead Sciences (NASDAQ:GILD) CFO Robin L. Washington sold 33,556 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $95.56, for a total transaction of $3,206,611.36. Following the completion of the sale, the chief financial officer now directly owns 49,832 shares of the company’s stock, valued at approximately $4,761,946. The sale was disclosed in a filing with the … Continue reading Stocks to Watch : Gilead Sciences Inc. (NASDAQ:GILD), Sprint (NYSE:S), DWSN, Prana Biotechnology Limited (NASDAQ:PRAN), Lime Energy (NASDAQ:LIME)

Chris Lewis08/2008/20

Nasdaq active movers: Facebook Inc (NASDAQ:FB), Sirius XM Holdings (NASDAQ:SIRI), QUALCOMM (NASDAQ:QCOM), Glu Mobile Inc. (NASDAQ:GLUU), Gilead Sciences, Inc. (NASDAQ:GILD)

Facebook Inc said the US Securities and Exchange Commission dropped its probe into the social networking company over events surrounding its controversial initial public offering. Facebook Inc (NASDAQ:FB) stock performance was 0.28% in last session and finished the day at $75.19. Traded volume was 385.00million shares in the last session and the average volume of the stock remained 49.28million shares. Facebook Inc (NASDAQ:FB) insider ownership … Continue reading Nasdaq active movers: Facebook Inc (NASDAQ:FB), Sirius XM Holdings (NASDAQ:SIRI), QUALCOMM (NASDAQ:QCOM), Glu Mobile Inc. (NASDAQ:GLUU), Gilead Sciences, Inc. (NASDAQ:GILD)

John Meady07/2807/28

Healthcare ACtive Stocks: MannKind (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Bristol-Myers Squibb Co (NYSE:BMY)

MannKind Corporation (NASDAQ: MNKD) is a small company based in Valencia, California, poised to launch its FDA approved drug, Afrezza, as treatment indications for both Type 1 and Type 2 diabetes. Despite near unanimous backing from experts at the Advisory Committee (ADCOM) and the medical community, Mr. Market is still pessimistic on the company. MannKind Corporation (NASDAQ:MNKD) stock performance was -2.50% in last session and finished the … Continue reading Healthcare ACtive Stocks: MannKind (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Bristol-Myers Squibb Co (NYSE:BMY)

Jason Knox07/2807/28

Investors Alert – Gilead Sciences (NASDAQ:GILD) , Galena Biopharma (NASDAQ:GALE) , RPI , UnitedHealth (NYSE:UNH) , China Automotive (NASDAQ:CAAS)

Gilead Sciences’ controversial $1,000-a-day Sovaldi pill is priced in line with previous treatments for Hepatitis C, but the nation’s health-care system likely won’t be able to handle that kind of sticker shock, and competition probably will bring down that price tag in coming months and years. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 4.84% in last session and finished the day at $89.19. Traded volume … Continue reading Investors Alert – Gilead Sciences (NASDAQ:GILD) , Galena Biopharma (NASDAQ:GALE) , RPI , UnitedHealth (NYSE:UNH) , China Automotive (NASDAQ:CAAS)

Jason Knox07/2107/21

Healthcare New Highs: Gilead Sciences (NASDAQ:GILD), Baxter International (NYSE:BAX), WellPoint (NYSE:WLP), The Cooper Companies, Inc. (NYSE:COO), iKang Healthcare (NASDAQ:KANG)

Gilead Sciences, Inc. (NASDAQ:GILD) on June 15 announced topline results from a Phase 3 clinical trial (GS-US-337-0113) in Japan evaluating the investigational once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection. Gilead Sciences, Inc. (NASDAQ:GILD) stock … Continue reading Healthcare New Highs: Gilead Sciences (NASDAQ:GILD), Baxter International (NYSE:BAX), WellPoint (NYSE:WLP), The Cooper Companies, Inc. (NYSE:COO), iKang Healthcare (NASDAQ:KANG)

Jayne Crisman07/1007/10

Healthcare Active Stocks: Arena Pharmaceuticals (NASDAQ:ARNA), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), TherapeuticsMD (NYSEMKT:TXMD), Boston Scientific (NYSE:BSX)

Arena Pharmaceuticals, Inc.’s (NASDAQ:ARNA ) shares dropped 9.4% following news that its CEO Jack Lief, has sold around 40% of his stake in the company. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was -5.29% in last session and finished the day at $5.01. Traded volume was 7.44million shares in the last session and the average volume of the stock remained 4.98million shares. The beta of the … Continue reading Healthcare Active Stocks: Arena Pharmaceuticals (NASDAQ:ARNA), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), TherapeuticsMD (NYSEMKT:TXMD), Boston Scientific (NYSE:BSX)

Kevin Long07/0907/09